Prescribing statins (lipid lowering drugs) prophylactically to try to reduce heart attacks has become big, big business. Just one drug, Lipitor, made by Pfizer, made $12.7 BILLION of sales last year alone. Health Insurance companies in the US, and the national GP contract in the UK reward doctors for putting patients with “high” cholesterol onto statins to produce lower blood levels in those patients. But does this do any good?
Many studies have shown that if you prescribe statins to people who have had a heart attack, then you are likely to reduce the rate of death from strokes and further heart attacks. For every 28 patients over 65 with heart disease who take statins, one life will be saved. The population based West of Scotland study showed you needed to treat 715 men to save one life.
However, studies of those without heart disease, and those aged over 70, have failed to show any significant lowering of mortality from the consumption of statins.
There are two other problems with statins – firstly, if they do what they say they do, they will reduce deaths from heart disease. What they don’t do is improve the quality of life of those who take them. Secondly, many experts believe the incidence and severity of side-effects from taking statins for many years is unknown, and probably underestimated.
We are right to be sceptical of drug company sponsored “evidence” when considering mass treatment of healthy individuals whose cholesterol level happens to fall outside the promoted “norms”. This is a problem which is widespread in medicine. A finding from one group of patients is turned into “evidence” and is then applied widely to groups of the population who are significantly different from the experimental group.




